Response of hypotensive dogs to dopamine hydrochloride and dobutamine hydrochloride during deep isoflurane anesthesia

Monica Rosati Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada.

Search for other papers by Monica Rosati in
Current site
Google Scholar
PubMed
Close
 DVM, DVSc
,
Doris H. Dyson Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada.

Search for other papers by Doris H. Dyson in
Current site
Google Scholar
PubMed
Close
 DVM, DVSc
,
Melissa D. Sinclair Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada.

Search for other papers by Melissa D. Sinclair in
Current site
Google Scholar
PubMed
Close
 DVM, DVSc
, and
William C. Sears Department of Population Medicine, Ontario Veterinary College, University of Guelph, Guelph, ON N1G 2W1, Canada.

Search for other papers by William C. Sears in
Current site
Google Scholar
PubMed
Close
 MS, MSc

Abstract

Objective—To evaluate the dose-related cardiovascular and urine output (UrO) effects of dopamine hydrochloride and dobutamine hydrochloride, administered individually and in combination at various ratios, and identify individual doses that achieve target mean arterial blood pressure (MAP; 70 mm Hg) and cardiac index (CI; 150 mL/kg/min) in dogs during deep isoflurane anesthesia.

Animals—10 young clinically normal dogs.

Procedures—Following isoflurane equilibration at a baseline MAP of 50 mm Hg on 3 occasions, dogs randomly received IV administration of dopamine (3, 7, 10, 15, and 20 μg/kg/min), dobutamine (1, 2, 4, 6, and 8 μg/kg/min), and dopamine-dobutamine combinations (3.5:1, 3.5:4, 7:2, 14:1, and 14:4 μg/kg/min) in a crossover study. Selected cardiovascular and UrO effects were determined following 20-minute infusions at each dose.

Results—Dopamine caused significant dose-dependent responses and achieved target MAP and CI at 7 μg/kg/min; dobutamine at 2 μg/kg/min significantly affected only CI values. At any dose, dopamine significantly affected UrO, whereas dobutamine did not. Target MAP and CI values were achieved with a dopamine-dobutamine combination at 7:2 μg/kg/min; a dopamine-related dose response for MAP and dopamine- and dobutamine-related dose responses for CI were identified. Changes in UrO were associated with dopamine only.

Conclusions and Clinical Relevance—In isoflurane-anesthetized dogs, a guideline dose for dopamine of 7 μg/kg/min is suggested; dobutamine alone did not improve MAP. Data regarding cardiovascular and UrO effects indicated that the combination of dopamine and dobutamine did not provide greater benefit than use of dopamine alone in dogs.

Abstract

Objective—To evaluate the dose-related cardiovascular and urine output (UrO) effects of dopamine hydrochloride and dobutamine hydrochloride, administered individually and in combination at various ratios, and identify individual doses that achieve target mean arterial blood pressure (MAP; 70 mm Hg) and cardiac index (CI; 150 mL/kg/min) in dogs during deep isoflurane anesthesia.

Animals—10 young clinically normal dogs.

Procedures—Following isoflurane equilibration at a baseline MAP of 50 mm Hg on 3 occasions, dogs randomly received IV administration of dopamine (3, 7, 10, 15, and 20 μg/kg/min), dobutamine (1, 2, 4, 6, and 8 μg/kg/min), and dopamine-dobutamine combinations (3.5:1, 3.5:4, 7:2, 14:1, and 14:4 μg/kg/min) in a crossover study. Selected cardiovascular and UrO effects were determined following 20-minute infusions at each dose.

Results—Dopamine caused significant dose-dependent responses and achieved target MAP and CI at 7 μg/kg/min; dobutamine at 2 μg/kg/min significantly affected only CI values. At any dose, dopamine significantly affected UrO, whereas dobutamine did not. Target MAP and CI values were achieved with a dopamine-dobutamine combination at 7:2 μg/kg/min; a dopamine-related dose response for MAP and dopamine- and dobutamine-related dose responses for CI were identified. Changes in UrO were associated with dopamine only.

Conclusions and Clinical Relevance—In isoflurane-anesthetized dogs, a guideline dose for dopamine of 7 μg/kg/min is suggested; dobutamine alone did not improve MAP. Data regarding cardiovascular and UrO effects indicated that the combination of dopamine and dobutamine did not provide greater benefit than use of dopamine alone in dogs.

All Time Past Year Past 30 Days
Abstract Views 229 0 0
Full Text Views 6617 5607 204
PDF Downloads 1650 827 84
Advertisement